Arbaclofen
Arbaclofen is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target gamma-aminobutyric acid type B receptor subunit 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
37 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | 1 | — | 1 |
| Hemiplegia | D006429 | HP_0011099 | G81.0 | — | — | — | 1 | — | 1 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autism spectrum disorder | D000067877 | HP_0000729 | F84.0 | — | 5 | 1 | — | 1 | 7 |
| Fragile x syndrome | D005600 | — | Q99.2 | — | 2 | 3 | — | 2 | 7 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | 6 | — | — | 6 |
| Muscle spasticity | D009128 | HP_0001257 | — | — | 1 | 2 | — | — | 3 |
| Charcot-marie-tooth disease | D002607 | EFO_0004148 | G60.0 | — | — | 2 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | 3 | — | — | — | 3 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 2 | — | — | — | 2 |
| Back pain | D001416 | HP_0003418 | M54 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Autistic disorder | D001321 | HP_0000717 | F84.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Arbaclofen |
| INN | arbaclofen |
| Description | Arbaclofen placarbil (/ɑːrˈbækloʊfɛn pləˈkɑːrbɪl/ ar-BAK-loh-fen plə-KAR-bil, also known as XP19986) is a prodrug of R-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC[C@H](CC(=O)O)c1ccc(Cl)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 69308-37-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL301742 |
| ChEBI ID | — |
| PubChem CID | 11281011 |
| DrugBank | DB08891 |
| UNII ID | NYU6UTW25B (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
GABBR1
GABBR1
Organism
Homo sapiens
Gene name
GABBR1
Gene synonyms
GPRC3A
NCBI Gene ID
Protein name
gamma-aminobutyric acid type B receptor subunit 1
Protein synonyms
GABA-B receptor, R1 subunit, gamma-aminobutyric acid (GABA) B receptor, 1, seven transmembrane helix receptor
Uniprot ID
Mouse ortholog
Gabbr1 (54393)
gamma-aminobutyric acid type B receptor subunit 1 (Q9WV18)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 774 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use